Centrum for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC, liver cancer) is the sixth most common tumor disease in the world. It generally develops on the basis of a previously damaged liver – a liver cirrhosis is already present in over 80% of cases. The cirrhosis is often caused by a chronic hepatitis B or C viral infection or longstanding alcoholism. In recent years, an increasing amount of HCCs based on fatty liver disease (so-called non-alcoholic steatohepatitis, NASH) have been detected. Patients with liver cirrhosis have a significantly increased risk of HCC, and it is thus recommended for these patients to receive an examination including an ultrasound every six months.
HCC Outpatient Clinic of the Gerok Liver Center:
Phone: 0761/270-33080
Fax: 0761/270-34470
Surgical Liver Consultation:
Phone: 0761/270-24440
Radiation therapy consultation hours:
Phone: 0761/270-94620
Nuclear Medicine Clinic:
Phone: 0761/270-39910
Clinic for Diagnostic and Interventional Radiology:
Phone: 0761/270-38580
Once the diagnosis is confirmed, the next step is to determine the tumor stage, which serves as a basis for setting the optimal and individual further course of therapy for the patient. These therapy decisions are made at an interdisciplinary tumor board, at which hepatologists, surgeons, interventional radiologists, radiotherapists, and nuclear medicine specialists work together to conceive an individual therapy plan for the patient.
We offer the following therapies:
- operation (including laparoscopic procedures and innovative surgical techniques, e.g., in-situ split)
- transcutaneous local ablative procedures (radiofrequency ablation, microwave ablation)
- transarterial procedures (transarterial chemoembolization = TACE, selective internal radiotherapy = SIRT)
- external radiation (stereotactic radiotherapy = SBRT)
- systemic drug therapy
- intravenous immunotherapy
- oral therapy with tyrosine kinase inhibitors
- various clinical therapy trials
Trials
Clinical trials at the Department of Medicine II: More information here (in German)
PD Dr. Michael Schultheiß
Telephone: +49 (0)761 270-33080
Fax: +49 (0)761 270-34470
PD Dr. Dominik Bettinger
Telephone: +49 (0)761 270-33080
Fax: +49 (0)761 270-34470
Department of Radiation Oncology
Dr. Tanja Schimek-Jasch
Telephone 0761 270-95201
Prof. Dr. Stefan Fichtner-Feigl
Telephone: +49 (0)761 270-24440
Dr. Philipp Holzner
Telephone: +49 (0)761 270-24440
Dr. Magdalena Menzel
Telephone: +49 (0)761 270-24440
Department of Radiation Oncology
Dr. Tanja Schimek-Jasch
Telephone 0761 270-95201
Department of Radiation Oncology
Dr. Tanja Schimek-Jasch
Telephone 0761 270-95201
Department of Nuclear Medicine
PD Dr. Dr. Christian Goetz
Telephone: +49 (0)761 270-39910
Department of Diagnostic and Interventional Radiology
Prof. Dr. Wibke Uller
Telephone: +49 (0)761 270-38580
Support groups for people with the same disease are an opportunity to exchange information and experiences without professional guidance as well as to give and receive emotional support. Find out more (in German)
When: Monday, 4 p.m.
Where: Small lecture hall, medicine
Board Management: PD Dr. Michael Schultheiß
0761 270-36140
michael.schultheiss@uniklinik-freiburg.de
Registration deadline: Friday, 12 noon
